Abstract

The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks. The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years. The reduction of viral hepatitis B incidence was achieved thanks to a higher vaccination coverage of both children and adults. The article presents an overview of monovalent and combination recombinant hepatitis B vaccines licensed in the Russian Federation. It describes the WHO position on preventive vaccination against viral hepatitis B, and pays special attention to vaccination of people at risk. The article considers promising areas for improving immunobiological products for hepatitis B prevention, including new technologies used in vaccine production, development and introduction of new adjuvants or adjuvants systems, and development of therapeutic vaccines.

Highlights

  • Представлены результаты ретроспективного анализа заболеваемости вирусным гепатитом В населения Российской Федерации с учетом применения вакцин Национального календаря профилактических прививок и Календаря профилактических прививок по эпидемическим показаниям за период с 2013 по 2017 г

  • The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks

  • The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years

Read more

Summary

Охват вакцинацией против гепатита В по годам

Показатель заболеваемости за период с 2013 по 2017 г. Снизился с 16,2 до 10,13 на 100 тыс. В рамках глобальной стратегии борьбы с вирусным гепатитом B на 2020 и 2030 гг. ВОЗ поставлены цели снизить число HBsAg-положительных детей в возрасте до 5 лет до 1 % к 2020 и до 0,1 % — к 2030 году

Вакцинопрофилактика гепатита B
Моновалентные вакцины
Вакцина гепатита В рекомбинантная дрожжевая
Индия ция против гепатита B показана
Комбинированные вакцины
Введение препарата в соответствии
Об авторах

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.